ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 11 of 50
Up
УЖМБС 2018, 3(7): 64–68
https://doi.org/10.26693/jmbs03.07.064
Clinical Medicine

Features of Treating Patients with Hypertension in Combination with Duodenal Ulcer in the Family Doctor’s Practice

Aleksandrova N. K., Reznichenko A. G., Vovk K. V., Nikolenko E. Y.
Abstract

In Ukraine, cardiovascular diseases account for 63% of the total mortality of the population. According to statistical data over the past 25 years, the prevalence of diseases of the circulatory system in Ukraine has tripled, and the death rate from them has increased by 45%. Duodenal ulcer in many countries remains one of the most urgent problems of gastroenterology. This is due to its high prevalence (10-15% of the total adult population), the prevailing debut of the disease in young and middle age, high rates of recurrence and complications. Material and methods. 42 patients were examined during the study. There were 26 men and 16 women with hypertension in combination with duodenal ulcer. The average age of patients was 53.1±1.7. All patients had hypertension of stage II. The control group consisted of 20 people. By the nature of antihypertensive therapy, the patients were divided into 2 groups: the first group comprised 21 patients receiving metoprolol 25-100 mg once a day, and the second group had 21 patients who were administered amlodipine 5-10 mg once a day. Results and discussion. Prior to treatment, patients in both groups complained on headache (42 persons), dizziness (31 persons), ear tension (19 people), palpitations and heart failure (33 persons), pain in the area of the heart (31 persons), pastosity of the legs and feet at the end of the day (18 persons), weakness and fatigue (33 persons), sleep disturbance (34 people). After the end of the therapy course, the majority of patients in both groups (38 patients) noted improvement in general mood and the disappearance of a number of clinical symptoms of hypertension. Drugs were well tolerated by all patients, new complaints did not appear. There were no cases of withdrawal of drugs. During treatment, we observed side effects in 2 patients receiving metoprolol (bradycardia with heart rate <50 per minute and weakness). In the group of patients receiving amlodipine no adverse effects were observed. Conclusion. The combined pathology of hypertension and duodenal ulcer affects the course of both diseases. Blockers of calcium channels, and in particular, amlodipine, can positively affect the treatment of combined pathology of hypertension and duodenal ulcer.

Keywords: hypertension, duodenal ulcer, treatment

Full text: PDF (Ukr) 199K

References
  1. Medyko-sotsialʹni aspekty khvorob systemy krovoobihu [Medical and social aspects of circulatory system diseases] Za red prof Kovalenka VM. Kiev; 2009.146 p. [Ukrainian]
  2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105-87. https://www.ncbi.nlm.nih.gov/pubmed/17563527. https://doi.org/10.1097/HJH.0b013e3281fc975a
  3. Svintsitsky A, Evtushenko O. Deyaki osoblyvosti likuvannya khvorykh iz poyednannyam hipertonichnoyi khvoroby z vyrazkovoyu khvoroboyu shlunka, dvanadtsyatypaloyi kyshky abo khronichnym hastroduodenitom [Some features of treatment of patients with a combination of hypertension with ulcers of the stomach, duodenal ulcer or chronic gastroduodenitis]. Liky Ukrayiny. 2004; 5: 127-30. [Ukrainian]
  4. Gorchakova N, Pritula R, Trohimchuk PV, ta in. Suchasnii stan ta perspektivy zastosuvannia preparativ amlodypynu v Ukraini [Current state and prospects for the use of amlodipine in Ukraine]. Liky Ukrayiny. 2004; 5; 114. [Ukrainian]
  5. Moiseev SV. Amlodipin: novyye dannyye kontroliruyemykh issledovaniy [Amlodipine: new data from controlled trials]. Klin. farmakol i terapia. 2003; 12(3): 59-62. [Ukrainian]
  6. Perceva TA, Cherkasova OG, Tischenko IV, Cigankova NM. Opyt primeneniya amlodipina v klinicheskoy praktike [Experience with amlodipine in clinical practice]. Ukr kardiol jorn. 2002; 5; 63–6. [Russian]
  7. Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, et al. Canadian Hypertension Education Program. The 2013 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol. 2012; 28: 270–87. https://www.ncbi.nlm.nih.gov/pubmed/23541660. https://doi.org/10.1016/j.cjca.2013.01.005
  8. Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013; 31: 2085–93. https://www.ncbi.nlm.nih.gov/pubmed/24107737. https://www.ncbi.nlm.nih.gov/pmc/articles/3771574. https://doi.org/10.1097/HJH.0b013e328363570c